Compare FLGT & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLGT | PRME |
|---|---|---|
| Founded | 2011 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 697.3M | 601.1M |
| IPO Year | 2016 | 2022 |
| Metric | FLGT | PRME |
|---|---|---|
| Price | $26.96 | $4.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $28.33 | $9.31 |
| AVG Volume (30 Days) | 272.3K | ★ 3.8M |
| Earning Date | 11-07-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $315,549,000.00 | $5,977,000.00 |
| Revenue This Year | $16.84 | $111.80 |
| Revenue Next Year | $9.74 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 13.61 | ★ 647.13 |
| 52 Week Low | $14.57 | $1.11 |
| 52 Week High | $31.04 | $6.94 |
| Indicator | FLGT | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 45.89 | 49.51 |
| Support Level | $26.69 | $3.95 |
| Resistance Level | $31.04 | $4.42 |
| Average True Range (ATR) | 0.74 | 0.31 |
| MACD | -0.44 | 0.10 |
| Stochastic Oscillator | 9.29 | 65.09 |
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.